1 Report Overview

1.1 Global Respiratory Inhalers Manufacturers Market Overview

1.2 Global Respiratory Inhalers Manufacturers Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who Is This Report for?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2 Introduction to Respiratory Inhalers

2.1 Respiratory Inhalers Overview

2.1.1 Nebulizers

2.1.2 Metered Dose Inhaler

2.1.3 Breath-Actuated Pressurised Metered-Dose Inhalers

2.1.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices

2.1.5 Dry powder inhalers (DPIs)

2.1.6 Soft Mist Inhalers

2.2 COPD Respiratory Inhalers Overview

2.2.1 Chronic Obstructive Pulmonary Disease Medications

2.2.1.1 Bronchodilators

2.2.1.2 Glucocorticoids

2.3 Asthma Respiratory Inhalers Overview

2.3.1 Desirable inhaler characteristics for treating asthma

2.4 Respiratory Inhalers – Realising Their Potential, Market Drivers

2.4.1 Combination Therapies - Respiratory Inhalers

2.4.1.1 LAMA/LABA combinations

2.4.1.2 LABA/ICS combination

2.4.1.3 LABA+LAMA vs. LABA+ICS combinations

2.4.2 Triple Combination - Respiratory Inhalers

2.4.2.1 LAMA/LABA/ICS “triple combination inhalers”

2.5 Market Restraints

2.6 Respiratory Inhalers: Trends and Developments

2.6.1 E-Technology in Asthma and COPD

3 Leading Respiratory Inhalers Products: Overview, 2018

3.1 The Global Respiratory Inhalers Market In 2018

3.2 Leading Companies in the Respiratory Inhalers Market, 2018

3.3 How Will Leading Companies’ Market Shares Change to 2028?

4 Leading Respiratory Inhalers Manufacturers Worldwide, 2018

4.1 Astrazeneca – Company Overview & Analysis

4.1.1 AstraZeneca Marketed Respiratory Inhalers

4.1.1.1 Latest developments related to Key Marketed Products

4.1.1.1.1 Symbicort: Recent Developments

4.1.1.1.2 Bevespi Aerosphere: Recent Developments

4.1.1.1.3 Tudorza/ Eklira Genuair: Recent Developments

4.1.1.1.4 Duaklir: Recent Developments

4.1.1.1.5 Fasenra: Recent Developments

4.1.1.1.6 Other Recent Developments

4.1.2 AstraZeneca Respiratory Inhalers R&D Pipeline & Future Outlook

4.1.2.1 Latest developments related to Key Pipeline Products

4.1.2.1.1 PT010/ PT009/ PT008/ PT005: Pipeline Developments

4.1.2.1.2 Fasenra: Pipeline Developments

4.1.2.1.3 Tezepelumab: Pipeline Developments

4.1.2.1.4 Tralokinumab: Pipeline Developments

4.1.3 AstraZeneca Respiratory Market Forecast, 2017-2028

4.2 Glaxosmithkline – Company Overview & Analysis

4.2.1 GlaxoSmithKline Marketed Respiratory Inhalers

4.2.1.1 Latest Developments related to Key Marketed Products

4.2.1.1.1 Relvar/Breo Ellipta: Recent Developments

4.2.1.1.2 Anoro Ellipta: Recent Developments

4.2.1.1.3 Nucala: Recent Developments

4.2.1.1.4 Seretide/Advair: Recent Developments

4.2.1.1.5 Trelegy Ellipta: Recent Developments

4.2.1.1.6 Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments

4.2.2 GlaxoSmithKline Respiratory Inhalers R&D Pipeline & Future Outlook

4.2.2.1 Latest developments related to Key Pipeline Products

4.2.2.1.1 Nucala: Recent Developments

4.2.3 GlaxoSmithKline Respiratory Market Forecast, 2017-2028

4.3 Boehringer Ingelheim – Company Overview & Analysis

4.3.1 Boehringer Ingelheim Marketed Respiratory Inhalers

4.3.1.1 Latest Developments related to Key Marketed Products

4.3.1.1.1 Spiriva Respimat: Recent Developments

4.3.1.1.1 Spiolto Respimat: Recent Developments

4.3.1.1.2 Ofev: Recent Developments

4.3.2 Boehringer Ingelheim Respiratory Inhalers R&D Pipeline & Future Outlook

4.3.3 Boehringer Ingelheim Respiratory Market Forecast, 2017-2028

4.4 Teva – Company Overview & Analysis

4.4.1 Teva Marketed Respiratory Inhalers

4.4.1.1 Latest developments related to Key Marketed Products

4.4.1.1.1 QVAR: Recent Developments

4.4.1.1.2 ProAir HFA: Recent Development

4.4.1.1.3 DuoResp Spiromax: Recent Developments

4.4.1.1.4 Aerivio Spiromax: Recent Developments

4.4.1.1.5 CINQAIR/CINQAERO: Recent Developments

4.4.1.1.6 AirDuo RespiClick / ArmonAir RespiClick: Recent Development

4.4.2 Teva Respiratory Inhalers R&D Pipeline & Future Outlook

4.4.2.1 Latest developments related to Key Pipeline Products

4.4.2.1.1 ProAir e-RespiClick: Recent Developments

4.4.3 Teva Respiratory Market Forecast, 2017-2028

4.5 Merck – Company Overview & Analysis

4.5.1 Merck Marketed Respiratory Inhalers

4.5.1.1 Latest Developments related to Key Marketed Products

4.5.1.1.1 Dulera: Recent Development

4.5.2 Merck Respiratory Inhalers R&D Pipeline & Future Outlook

4.5.3 Merck Respiratory Market Forecast, 2017-2028

4.6 Roche – Company Overview & Analysis

4.6.1 Roche Marketed Respiratory Inhalers

4.6.1.1 Latest Developments related to Key Marketed Products

4.6.1.1.1 Xolair: Recent Developments

4.6.2 Roche Respiratory Inhalers R&D Pipeline & Future Outlook

4.6.2.1 Latest Developments related to Key Pipeline Products

4.6.2.1.1 RG3637: Pipeline Developments

4.6.3 Roche Respiratory Market Forecast, 2017-2028

4.7 Novartis – Company Overview & Analysis

4.7.1 Novartis Marketed Respiratory Inhalers

4.7.1.1 Latest developments related to Key Marketed Products

4.7.1.1.1 Ultibro Breezhaler: Recent Developments

4.7.1.1.2 Xolair: Recent Developments

4.7.2 Novartis Respiratory Inhalers R&D Pipeline & Future Outlook

4.7.2.1 Latest developments related to Key Pipeline Products

4.7.2.1.1 QAW039: Pipeline Developments

4.7.2.1.2 QBW251: Pipeline Developments

4.7.2.1.3 QVM149: Pipeline Developments

4.7.2.1.4 CSJ117: Pipeline Developments

4.7.2.1.5 CJM112: Pipeline Developments

4.7.3 Novartis Respiratory Market Forecast, 2017-2028

4.8 Mundipharma – Company Overview & Analysis

4.8.1 Mundipharma Marketed Respiratory Inhalers

4.8.1.1 Latest Developments related to Key Marketed Products

4.8.1.1.1 Flutiform (fluticasone propionate and formoterol): Recent Developments

4.8.1.1.2 Company Related Developments

4.8.2 Mundipharma Respiratory Inhalers R&D Pipeline & Future Outlook

4.8.2.1 Latest Developments related to Key Pipeline Products

4.8.2.1.1 Flutiform k-haler (fluticasone propionate and formoterol): Recent Developments

4.9 Pari Medical Holding – Company Overview & Analysis

4.9.1 PARI Medical Holding Marketed Respiratory Inhalers

4.9.1.1 Latest Developments related to Key Marketed Products

4.9.1.1.1 SUN-101: Recent Developments

4.9.2 PARI Pharma Respiratory Inhalers R&D Pipeline & Future Outlook

4.9.2.1 Latest Developments related to Key Pipeline Products

4.9.2.1.1 Cyclosporin A: Recent Developments

4.10 Omron Healthcare Europe B.V– Company Overview & Analysis

4.10.1 Omron Healthcare Europe B.V: Marketed Respiratory Products

4.10.1.1 Latest Developments related to Company

4.10.1.1.1 Company Recent Developments

4.11 Cipla– Company Overview & Analysis

4.11.1 Cipla Marketed Respiratory Inhalers

4.11.1.1 Latest Developments related to Key Marketed Products

4.11.1.1.1 Budesonide Inhalation Suspension: Pipeline Developments

4.11.1.1.2 SynchroBreathe: Pipeline Developments

4.11.1.2 Cipla Launch Plans for Respiratory Products

4.12 Sunovion Pharmaceuticals– Company Overview & Analysis

4.12.1 Sunovion Pharmaceuticals: Marketed Respiratory Inhalers

4.12.1.1 Latest Developments related to Key Marketed Products

4.12.1.1.1 SUN-101: Recent Developments

4.12.2 Sunovion Pharmaceuticals Respiratory Inhalers R&D Pipeline & Future Outlook

4.12.3 Sunovion Respiratory Market Forecast, 2017-2028

4.13 Aerocrine (Circassia)– Company Overview & Analysis

4.13.1 Circassia Marketed Respiratory Inhalers

4.13.1.1 Latest Developments related to Key Marketed Products

4.13.1.1.1 NIOX: Recent Developments

4.13.1.1.2 Tudorza Pressair: Recent Developments

4.13.2 Circassia Respiratory Inhalers R&D Pipeline & Future Outlook

4.13.2.1 Latest Developments related to Key Pipeline Products

4.13.2.1.1 Duaklir Pressair US: Pipeline Developments

4.13.3 Circassia Respiratory Market Forecast, 2017-2028

4.14 H&T Presspart – Company Overview & Analysis

4.14.1 H&T Presspart Marketed Respiratory Inhalers

4.14.1.1 Latest Developments related to the Company

4.14.1.1.1 Recent Developments

4.14.2 H&T Presspart Respiratory Inhalers R&D Pipeline & Future Outlook

4.14.3 H&T Presspart Respiratory Market Forecast, 2017-2028

4.15 Beximco Pharmaceuticals Ltd.– Company Overview & Analysis

4.15.1 Beximco Pharmaceuticals Marketed Respiratory Inhalers

4.15.2 Beximco Respiratory Inhalers R&D Pipeline & Future Outlook

4.15.3 Beximco Respiratory Market Forecast, 2017-2028

4.16 Chiesi Farmaceutici S.p.A. – Company Overview & Analysis

4.16.1 Chiesi Farmaceutici S.p.A Marketed Respiratory Inhalers

4.16.1.1 Latest Developments related to Key Marketed Products

4.16.1.1.1 Trimbow: Recent Developments

4.16.2 Chiesi Farmaceutici Respiratory Inhalers R&D Pipeline & Future Outlook

4.16.2.1 Latest Developments related to Key Pipeline Products

4.16.2.1.1 Bronchitol: Recent development

4.16.2.1.2 CHF 6297: Recent development

4.16.3 Chiesi Farmaceutici: Respiratory Market Forecast, 2017-2028

4.17 Pulmatrix: Company Overview & Analysis

4.17.1 Pulmatrix Respiratory Inhalers R&D Pipeline & Future Outlook

4.17.1.1 Latest Developments related to Key Pipeline Products

4.17.1.1.1 PUR0200-US: Recent development

4.17.1.1.2 PUR1900: Recent development

4.18 Fluidda– Company Overview & Analysis

4.18.1 Latest Developments related to the Company

4.19 Pneuma Respiratory – Company Overview & Analysis

4.19.1 Latest Developments related to the Company

4.20 Amiko Digital Health– Company Overview & Analysis

4.20.1 Amiko Digital Health Marketed Respiratory Inhaler Product

5 Conclusions

5.1 Respiratory Inhalers: A Maturing Market

5.2 The Global Respiratory Inhalers Manufacturers Market In 2018

5.3 Leading Respiratory Inhalers Companies

5.4 Global Respiratory Inhalers Market Forecast 2017-2028

5.5 The Future of the Respiratory Inhalers Market

5.5.1 Growth in Anti-Inflammatory and Combination Drugs

5.5.2 Personalised Medicine

5.5.3 Unmet Needs in Asthma and COPD

5.6 Strategies for Growth In 2018-2028

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

TABLE 2.1 ADVANTAGES AND DISADVANTAGES OF THE MAIN TYPES OF ASTHMA INHALERS

TABLE 2.2 E-TECHNOLOGY BASED INHALERS

TABLE 3.1 GLOBAL MARKET FORECASTS: REVENUES ($BN), AGR (%) AND CAGR (%), BY LEADING COMPANIES, 2017-2028

TABLE 3.2 LEADING COMPANIES IN RESPIRATORY INHALERS

TABLE 3.3 LEADING RESPIRATORY INHALERS MANUFACTURERS: REVENUES ($BN) AND MARKET SHARES (%), 2018 AND 2028

TABLE 4.1 ASTRAZENECA: COMPANY OVERVIEW, 2018

TABLE 4.2 ASTRAZENECA: PRODUCTS PORTFOLIO, 2018

TABLE 4.3 ASTRAZENECA: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.4 ASTRAZENECA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.5 GLAXOSMITHKLINE: COMPANY OVERVIEW, 2018

TABLE 4.6 GLAXOSMITHKLINE: PRODUCTS PORTFOLIO, 2018

TABLE 4.7 GLAXOSMITHKLINE: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.8 GLAXOSMITHKLINE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.9 BOEHRINGER INGELHEIM: COMPANY OVERVIEW, 2018

TABLE 4.10 BOEHRINGER INGELHEIM: PRODUCTS PORTFOLIO, 2018

TABLE 4.11 BOEHRINGER INGELHEIM: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.12 TEVA: COMPANY OVERVIEW, 2018

TABLE 4.13 TEVA: PRODUCTS PORTFOLIO, 2018

TABLE 4.14 TEVA: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.15 TEVA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.16 MERCK: COMPANY OVERVIEW, 2018

TABLE 4.17 MERCK: PRODUCTS PORTFOLIO, 2018

TABLE 4.18 MERCK: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.19 ROCHE: COMPANY OVERVIEW, 2018

TABLE 4.20 ROCHE: PRODUCTS PORTFOLIO, 2018

TABLE 4.21 ROCHE: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.22 ROCHE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.23 NOVARTIS: COMPANY OVERVIEW, 2018

TABLE 4.24 NOVARTIS: PRODUCTS PORTFOLIO, 2018

TABLE 4.25 NOVARTIS: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.26 NOVARTIS: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.27 MUNDIPHARMA: COMPANY OVERVIEW, 2018

TABLE 4.28 MUNDIPHARMA: PRODUCTS PORTFOLIO, 2018

TABLE 4.29 MUNDIPHARMA: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.30 PARI MEDICAL HOLDING: COMPANY OVERVIEW, 2018

TABLE 4.31 PARI MEDICAL HOLDING: PRODUCTS PORTFOLIO, 2018

TABLE 4.32 PARI MEDICAL HOLDING: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.33 OMRON HEALTHCARE EUROPE B.V: COMPANY OVERVIEW, 2018

TABLE 4.34 OMRON HEALTHCARE EUROPE B.V: PRODUCTS PORTFOLIO, 2018

TABLE 4.35 CIPLA: COMPANY OVERVIEW, 2018

TABLE 4.36 CIPLA: PRODUCTS PORTFOLIO, 2018

TABLE 4.37 SUNOVION PHARMACEUTICALS: COMPANY OVERVIEW, 2018

TABLE 4.38 SUNOVION PHARMACEUTICALS: PRODUCTS PORTFOLIO, 2018

TABLE 4.39 SUNOVION: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.40 CIRCASSIA: COMPANY OVERVIEW, 2018

TABLE 4.41 CIRCASSIA: PRODUCTS PORTFOLIO, 2018

TABLE 4.42 CIRCASSIA: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.43 H&T PRESSPART: COMPANY OVERVIEW, 2018

TABLE 4.44 H&T PRESSPART: PRODUCTS PORTFOLIO, 2018

TABLE 4.45 BEXIMCO PHARMACEUTICALS: COMPANY OVERVIEW, 2018

TABLE 4.46 BEXIMCO PHARMACEUTICALS: PRODUCTS PORTFOLIO, 2018

TABLE 4.47 CHIESI FARMACEUTICI S.P.A: COMPANY OVERVIEW, 2018

TABLE 4.48 CHIESI FARMACEUTICI S.P.A: PRODUCTS PORTFOLIO, 2018

TABLE 4.49 CHIESI FARMACEUTICI S.P.A: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.50 CHIESI FARMACEUTICI S.P.A: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028

TABLE 4.51 PULMATRIX: COMPANY OVERVIEW, 2018

TABLE 4.52 PULMATRIX: PRODUCTS PIPELINE PORTFOLIO, 2018

TABLE 4.53 FLUIDDA: COMPANY OVERVIEW, 2018

TABLE 4.54 PNEUMA RESPIRATORY: COMPANY OVERVIEW, 2018

TABLE 4.55 AMIKO DIGITAL HEALTH: COMPANY OVERVIEW, 2018



List of Figures

FIGURE 1.1 GLOBAL RESPIRATORY INHALERS MANUFACTURERS MARKET SEGMENTATION OVERVIEW, 2018

FIGURE 2.1 STEPWISE APPROACH TO TREATMENT OF COPD

FIGURE 3.1 GLOBAL: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 3.2 LEADING RESPIRATORY MANUFACTURERS: REVENUE ($BN), 2018

FIGURE 3.3 LEADING RESPIRATORY MANUFACTURERS: MARKET SHARE (%), 2018

FIGURE 3.4 LEADING RESPIRATORY INHALERS MANUFACTURERS: REVENUES ($M), 2028

FIGURE 3.5 LEADING RESPIRATORY INHALERS MANUFACTURERS: MARKET SHARES (%), 2028

FIGURE 4.1 ASTRAZENECA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.2 GLAXOSMITHKLINE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.3 BOEHRINGER INGELHEIM: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.4 TEVA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.5 MERCK: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.6 ROCHE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.7 NOVARTIS: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.8 SUNOVION RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 4.9 CHIESI FARMACEUTICI RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028

FIGURE 5.1 WORLD RESPIRATORY INHALERS MARKET FORECAST: REVENUES ($M), 2017-2028